A study led by researchers from MD Anderson Cancer Center shows that radiation or surgical removal of metastatic tumors provides a major survival advantage for lung cancer patients with minimal stage IV disease who have not progressed after frontline chemotherapy.
Taiho Oncology Inc. and Servier jointly announced the clinical data from the pivotal phase III trial evaluating Lonsurf (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pretreated metastatic gastric/gastroesophageal junction cancers who have progressed or are intolerant to previous lines of therapy.
AVEO Oncology and EUSA Pharma announced the presentation of updated interim results from the phase II portion of the TiNivo study, a phase Ib/II multicenter trial of oral tivozanib (Fotivda) in combination with intravenous nivolumab (Opdivo, Bristol-Myers Squibb) for the treatment of advanced or metastatic renal cell carcinoma.
Celsion Corporation announced results from its dose escalating phase IB OVATION I trial evaluating neoadjuvant chemotherapy treatment for six cycles and GEN-1 given weekly for a total of eight doses prior to interval debulking surgery in newly diagnosed patients with stage III/IV ovarian cancer.
A systematic review and meta-analysis from the Regenstrief Institute and Indiana University School of Medicine has found that, in spite of the higher incidence and death rate of colorectal cancer in blacks, no difference exists in the overall prevalence of advanced, precancerous polyps between average-risk blacks and whites who underwent a screening colonoscopy.
A publication by UT Southwestern researchers focuses on biology of formation of disfiguring skin tumors associated with neurofibromatosis type 1.
The pivotal phase III KEYNOTE-426 trial investigating Keytruda (pembrolizumab), Merck's anti-PD-1 therapy, in combination with Inlyta (axitinib), Pfizer's tyrosine kinase inhibitor, met both primary endpoints of overall survival and progression-free survival in the first-line treatment of advanced or metastatic renal cell carcinoma.
A new study demonstrates that patients can safely use skin creams before undergoing radiation therapy. This contradicts common advice from radiation oncologists, according to researchers at Washington University School of Medicine in St. Louis and the University of Pennsylvania.
Researchers from MIT and Massachusetts General Hospital have developed an automated model that assesses dense breast tissue in mammograms—which is an independent risk factor for breast cancer—as reliably as expert radiologists.
A drug first identified 150 years ago and used as a smooth-muscle relaxant might make tumors more sensitive to radiation therapy, according to a recent study led by researchers at Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
